The case of a 33-year-old female patient with clear cell mRCC who developed metastatic progression after undergoing curative-intent surgery, presenting with vertebral bone metastasis at C7 and peritoneal carcinomatosis is reported.
Michela Izzo, A. Pappalardo, Andrea D'Arienzo et al.· Drugs in Context· 1 citation
In clinically fit older patients, combination-based first-line and maintenance treatment was associated with improved OS and PFS, and these findings argue against routine de-escalation strategies on the basis of age alone.
D. Incognito, A. D'arienzo, C. Barraco et al.· The Oncologist· 0 citations
PARP inhibitors have become an integral component of treatment strategies for advanced epithelial ovarian cancer, particularly in BRCA1/2-mutated and homologous recombination-deficient (HRD) tumors. Despite clinically meaningful improvements in progression-free survival, a substantial proportion of patients develop pri...
D. Incognito, G. Ciappina, G. Ettore et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.